Feedback / Questions
Imfinzi (durvalumab) - AstraZeneca
venadaparib (NOV 1401) - National OncoVenture, Ildong
Keytruda (pembrolizumab) - Merck (MSD)
http://clinicaltrials.gov/ct2/show/NCT07269158
Dec 9, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next